• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Janux Therapeutics raises $56M Series A for T cell engager tech

March 3, 2021 By Sean Whooley

Janux TherapeuticsJanux Therapuetics announced today that it closed a $56 million Series A financing as it develops its T cell engager technology.

Avalon Ventures led the financing round, while new investors OrbiMed and RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner Jake Simson will join Janux’s board of directors, according to a news release.

Funding is set to help San Diego-based Janux as it develops its proprietary tumor-activated T cell engager (TRACTr) technology designed to overcome the current limitations in T cell immuno-oncology therapies. TRACTr technology is designed to integrate tumor-specific activation with crossover pharmacokinetics to produce strong T cell engager therapeutics.

Janux’s TRACTr drug candidates have demonstrated comparable anti-tumor efficacy related to standard T cell engagers, the company said, but don’t have the associated liabilities related to cytokine release, healthy tissue toxicities or systemic immune activation.

The money raised will be used to advance the company’s preclinical pipeline, which includes the TROP2-TRACTr and PSMA-TRACTr, as the company expects to advance its first candidate into the clinic in the first half of next year.

“We are pleased to close this financing round with a top-tier investor syndicate who recognize the potential of our TRACTr technology to engineer best-in-class T cell engagers to provide better outcomes for cancer patients,” Janux president & CEO David Campbell said in the release. “With this financing, we’re focused on advancing our deep pipeline of T cell engager immunotherapies for the treatment of various cancers. We anticipate that the first of several development candidates will be entering the clinic next year for a solid tumor indication.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Janux Therapeutics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS